News Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 03/09/2026 +04			5-day change	1st Jan Change
56.10 ^USD	+0.38%		-6.56%	+27.36%

08-21	Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says	MT
08-21	Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating	MT

All News

Mentions Relevance

09-02	Scholar Rock Receives FDA Fast Track Designation For Apitegromab Facioscapulohumeral Muscular Dystrophy Program As Participant Dosing Commences In Phase 2 FORGE Trial	CI
09-02	Scholar Rock Gets FDA Fast Track, Orphan Drug Designations for Muscular Disorder Drug	MT
09-02	Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial	BU
08-27	Scholar Rock to Present at Upcoming Investor Conferences	BU
08-21	Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says	MT
08-21	Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating	MT
08-21	Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission	RE
08-21	Scholar Rock Announces Removal Of Catalent Indiana As Fill-Finish Facility And Progresses Apitegromab Regulatory Filings With FDA, EMA, And PMDA	CI
08-21	Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan	CI
08-21	Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility	MT
08-21	Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan	BU
08-15	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
08-10	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date	MT
08-08	Scholar Rock drops Novo Nordisk facility from marketing application for muscle weakness drug	RE
08-08	Scholar Rock Holdings Pulls Novo Nordisk Facility From Drug Application After FDA Flag	DJ
08-08	Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date	MT
08-08	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date	BU
08-06	Scholar Rock Holding Corporation, Q2 2026 Earnings Call, Aug 06, 2026
08-06	Scholar Rock Holding Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Scholar Rock Q2 Net Loss Narrows	MT
08-06	Scholar Rock Reports Apitegromab Biologics License Application Progress, Initiates Phase 2 Forge Study, and Provides Updates on Srk-439 and Opal Trials	CI
08-06	Earnings Flash (SRRK) Scholar Rock Posts Q2 Loss of $0.84 a Share, vs. FactSet Est of $0.84 Loss	MT
08-06	Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights	BU
07-29	Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference	BU
07-20	Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026	RE